AAAAAA
Results: 1-25/29
Authors:
Mathijssen, RHJ
van Alphen, RJ
Verweij, J
Loos, WJ
Nooter, K
Stoter, G
Sparreboom, A
Citation: Rhj. Mathijssen et al., Clinical pharmacokinetics and metabolism of irinotecan (CPT-11), CLIN CANC R, 7(8), 2001, pp. 2182-2194
Authors:
Schellens, JHM
Dombernowsky, P
Cassidy, J
Epelbaum, R
Dirix, L
Cox, EH
Wanders, J
Calabresi, F
Paridaens, R
Monfardini, S
Wolff, J
Loos, WJ
Verweij, J
Pavlidis, N
Hanauske, AR
Citation: Jhm. Schellens et al., Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9, ANTI-CANC D, 12(7), 2001, pp. 583-590
Authors:
Kehrer, DFS
Soepenberg, O
Loos, WJ
Verweij, J
Sparreboom, A
Citation: Dfs. Kehrer et al., Modulation of camptothecin analogs in the treatment of cancer: a review, ANTI-CANC D, 12(2), 2001, pp. 89-105
Authors:
de Jongh, FE
Verweij, J
Loos, WJ
de Wit, R
de Jonge, MJA
Planting, AST
Nooter, K
Stoter, G
Sparreboom, A
Citation: Fe. De Jongh et al., Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure, J CL ONCOL, 19(17), 2001, pp. 3733-3739
Authors:
Sparreboom, A
Nooter, K
Loos, WJ
Verweij, J
Citation: A. Sparreboom et al., The (ir)relevance of plasma protein binding of anticancer drugs, NETH J MED, 59(4), 2001, pp. 196-207
Authors:
Gelderblom, H
Sparreboom, A
de Jonge, MJA
Loos, WJ
Wilms, E
Mantel, MA
Hennis, B
Camlett, I
Verweij, J
van der Burg, MEL
Citation: H. Gelderblom et al., Dose and schedule-finding study of oral topotecan and weekly cisplatin in patients with recurrent ovarian cancer, BR J CANC, 85(8), 2001, pp. 1124-1129
Authors:
Loos, WJ
Kehrer, D
Brouwer, E
Verweij, J
de Bruijn, P
Hamilton, M
Gill, S
Nooter, K
Stoter, G
Sparreboom, A
Citation: Wj. Loos et al., Liposomal lurtotecan (NX211): determination of total drug levels in human plasma and urine by reversed-phase high-performance liquid chromatography, J CHROMAT B, 738(1), 2000, pp. 155-163
Authors:
Loos, WJ
Gelderblom, H
Sparreboom, A
Verweij, J
de Jonge, MJA
Citation: Wj. Loos et al., Inter- and intrapatient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens, CLIN CANC R, 6(7), 2000, pp. 2685-2689
Authors:
Gelderblom, H
Loos, WJ
Verweij, J
de Jonge, MJA
Sparreboom, A
Citation: H. Gelderblom et al., Topotecan lacks third space sequestration, CLIN CANC R, 6(4), 2000, pp. 1288-1292
Authors:
Loos, WJ
Gelderblom, HJ
Verweij, J
Brouwer, E
de Jonge, MJA
Sparreboom, A
Citation: Wj. Loos et al., Gender-dependent pharmacokinetics of topotecan in adult patients, ANTI-CANC D, 11(9), 2000, pp. 673-680
Authors:
Loos, WJ
de Bruijn, P
Verweij, J
Sparreboom, A
Citation: Wj. Loos et al., Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography, ANTI-CANC D, 11(5), 2000, pp. 315-324
Authors:
van Zuylen, L
Gianni, L
Verweij, J
Mross, K
Brouwer, E
Loos, WJ
Sparreboom, A
Citation: L. Van Zuylen et al., Inter-relationships of paclitaxel disposition, infusion duration and Cremophor EL kinetics in cancer patients, ANTI-CANC D, 11(5), 2000, pp. 331-337
Authors:
Gelderblom, AJ
Loos, WJ
de Jonge, MJA
Sparreboom, A
Planting, AST
van der Burg, MEL
Brouwer, E
Verheij, C
Ouwens, L
Hearn, S
Verweij, J
Citation: Aj. Gelderblom et al., Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin, ANN ONCOL, 11(9), 2000, pp. 1205-1207
Authors:
de Jonge, MJA
Loos, WJ
Gelderblom, H
Planting, AST
van der Burg, MEL
Sparreboom, A
Brouwer, E
van Beurden, V
Mantel, MA
Doyle, E
Hearn, S
Ross, G
Verweij, J
Citation: Mja. De Jonge et al., Phase I pharmacologic study of oral topotecan and intravenous cisplatin: Sequence-dependent hematologic side effects, J CL ONCOL, 18(10), 2000, pp. 2104-2115
Authors:
Brouwer, E
Verweij, J
De Bruijn, P
Loos, WJ
Pillay, M
Buijs, D
Sparreboom, A
Citation: E. Brouwer et al., Measurement of fraction unbound paclitaxel in human plasma, DRUG META D, 28(10), 2000, pp. 1141-1145
Authors:
Loos, WJ
de Bruijn, P
van Zuylen, L
Verweij, J
Nooter, K
Stoter, G
Sparreboom, A
Citation: Wj. Loos et al., Determination of 5-fluorouracil in microvolumes of human plasma by solventextraction and high-performance liquid chromatography, J CHROMAT B, 735(2), 1999, pp. 293-297
Authors:
Sparreboom, A
Loos, WJ
Nooter, K
Stoter, G
Verweij, J
Citation: A. Sparreboom et al., Liquid chromatographic analysis and preliminary pharmacokinetics of methotrexate in cancer patients co-treated with docetaxel, J CHROMAT B, 735(1), 1999, pp. 111-119
Authors:
Gerrits, CJH
Schellens, JHM
Burris, H
Eckardt, JR
Planting, AST
van der Burg, MEL
Rodriguez, GI
Loos, WJ
van Beurden, V
Hudson, I
Von Hoff, DD
Verweij, J
Citation: Cjh. Gerrits et al., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (hycamtin), CLIN CANC R, 5(1), 1999, pp. 69-75
Authors:
Loos, WJ
Verweij, J
Gelderblom, HJ
de Jonge, MJA
Brouwer, E
Dallaire, BK
Sparreboom, A
Citation: Wj. Loos et al., Role of erythrocytes and serum proteins in the kinetic profile of total 9-amino-20(S)-camptothecin in humans, ANTI-CANC D, 10(8), 1999, pp. 705-710
Authors:
Sparreboom, A
Planting, AST
Jewell, RC
van der Burg, MEL
van der Gaast, A
de Bruijn, P
Loos, WJ
Nooter, K
Chandler, LH
Paul, EM
Wissel, PS
Verweij, J
Citation: A. Sparreboom et al., Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein, ANTI-CANC D, 10(8), 1999, pp. 719-728
Authors:
van Zuylen, L
Schellens, JHM
Goey, SH
Pronk, LC
de Boer-Dennert, MM
Loos, WJ
Ma, JG
Stoter, G
Verweij, J
Citation: L. Van Zuylen et al., Phase I and pharmacologic study of the arotinoid Ro 40-8757 in combinationwith cisplatin and etoposide in patients with non-small cell lung cancer, ANTI-CANC D, 10(4), 1999, pp. 361-368
Authors:
Mathijssen, RHJ
van Alphen, RJ
de Jonge, MJA
Verweij, J
de Bruijn, P
Loos, WJ
Nooter, K
Vernillet, L
Stoter, G
Sparreboom, A
Citation: Rhj. Mathijssen et al., Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin, ANTI-CANC D, 10(1), 1999, pp. 9-16
Authors:
de Jonge, MJA
Punt, CJA
Gelderblom, AH
Loos, WJ
van Beurden, V
Planting, AST
van der Burg, MEL
van Maanen, LWGM
Dallaire, BK
Verweij, J
Wagener, T
Sparreboom, A
Citation: Mja. De Jonge et al., Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors, J CL ONCOL, 17(7), 1999, pp. 2219-2226
Authors:
Straathof, CSM
van den Bent, MJ
Loos, WJ
Vecht, CJ
Schellens, JHM
Citation: Csm. Straathof et al., The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration, J NEURO-ONC, 42(2), 1999, pp. 117-122
Authors:
Sparreboom, A
De Jonge, MJA
Punt, CJA
Loos, WJ
Nooter, K
Stoter, G
Porro, MG
Verweij, J
Citation: A. Sparreboom et al., Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis, DRUG META D, 27(7), 1999, pp. 816-820